
Clinical Trials Flowcharts

May 2025

Table of Contents

[Breast](#)

[GI](#)

[GU](#)

[Gynecologic](#)

[Head & Neck](#)

[Leukemia](#)

[Lymphoma](#)

[Melanoma](#)

[Myeloma](#)

[Neuroendocrine](#)

[Sarcoma](#)

[Thoracic](#)

[Cancer Services – Quad Cities](#)



To refer a patient:

To learn more about a specific trial, contact the MOG leader listed, or call the clinical trials hotline at 319-353-8155.

All calls to the clinical trials hotline will be returned within 48 hours.

The clinical trials team will then work with you to get your patient enrolled, when appropriate.

Clinical Trials Hotline
319-353-8155



Mimi McKay, MPH, BSN
Clinical Trial Navigator
mariel-mckay@uiowa.edu

Breast Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

BREAST CANCER



OPEN



PENDING


NEOADJUVANT TNBC

SCARLET: T2-T4,
N0, M0 or T1-T3,
N1-2, M0; no prior
systemic therapy or
radiation therapy
with curative intent
for current breast
cancer

PI: Sneha Phadke

[NCT05929768](#)

BREAST CANCER



BREAST CANCER



OPEN



PENDING

METASTATIC HER2+

Beamicon BCGC-1:
Documented HER2+
metastatic breast
cancer with
presence of at least
one RECIST
measurable lesion

PI: Sneha Phadke

[NCT06324357](#)

LuMIERE:
Progressed on ≥ 2
lines of HER2
targeted therapy
for metastatic
disease,
measurable
disease, can
continue treatment
up to 14 days of
C1D1.

PI: Yusuf Menda

[NCT04939610](#)


BREAST CANCER



OPEN



PENDING




BREAST CANCER



OPEN



PENDING



Gastrointestinal Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

PANCREATIC CANCER




OPEN




PENDING

NON-
RESECTABLE



METASTATIC



COLORECTAL CANCER

☐ OPEN

☐ PENDING

NEOADJUVAN

T

Dostarlimab
Criteria: Biopsy proven Stage II or III dMMR amenable to en bloc surgical resection; biopsy specimen has enough tissue for 4-6 FFPE slides; absence of metastatic disease

PI: Saima Sharif

NCT05239546

ADJUVANT

NRG-GI008
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing


PI: Saima Sharif

NCT05174169

COLORECTAL CANCER

OPEN

PENDING



GASTRIC/GASTROESOPHAGEAL CANCER



OPEN



PENDING

1L

A022102

Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

PI: Saima Sharif

[NCT05677490](#)

METASTATIC

OBT076-001:

Criteria: Non-curative recurrent and/or metastatic solid tumors for which a standard therapy is not available or is no longer effective; maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting

PI: Doug Laux

[NCT04064359](#)

Beamicon BCGC-1:

Documented HER2+ gastric, GEJ, or esophageal adenocarcinoma with presence of at least one RECIST measurable lesion

PI: Sneha Phadke

[NCT06324357](#)

ACCRU GI-1810:

Criteria: LA, unresectable, metastatic disease that has progressed ≤ 180 days from last treatment, patient must have received 5-FU or capecitabine and platinum or trastuzumab in case of HER2+ disease

PI: Saima Sharif

[NCT046607](#)

[60](#)

TWINPEAK

Criteria: 2L Locally advanced or metastatic GC/GEJ; measurable disease

PI: Naomi Fei

[NCT05482893](#)

BILIARY TRACT CANCER



☐ OPEN

☐ PENDING

Adjuvant

ARTEMIDE-Biliary01:
Criteria: Histologically confirmed adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma (CCA) or muscle invasive gallbladder cancer (GBC)) after macroscopically complete resection (R0 or R1); randomization within 12 weeks after resection

PI: Naomi Fei

[NCT06109779](#)

HEPATOCELLULAR CARCINOMA



OPEN



PENDING

UNRESECTABL

ROUTE90:

Criteria: Confirmed diagnosis of HCC, LIRADS 5 or biopsy; One lesion ≥ 2 cm in diameter, no more than 3 lesions; Max 3 lesions and single lesion size ≤ 8 cm & sum tumor dimensions of ≤ 12 cm; Evidence that $> 33\%$ of the total liver volume is disease-free; No extra hepatic disease

PI: Michael Hummel

[NCT05953337](#)

Genitourinary Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

BLADDER CANCER

OPEN

PENDING

NMIBC

Adapt

Criteria: Histologically confirmed urothelial carcinoma of bladder (Ta, T1, or Tis) on TURBT; BCG unresponsive disease (persistent CIS with or without the presence of Ta or T1 tumors within 12 months of completion of BCG, or recurrent high-grade Ta or T1 tumors within 6 months of completion of adequate BCG therapy

PI: Michael O'Donnell

[NCT03317158](#)

Bridge

Criteria: High-grade non-muscle invasive urothelial carcinoma of the bladder; must have all visible papillary tumor resected by the treating urologist at the site registering the patient; no prior intravesical therapy for bladder cancer with the exception of perioperative chemotherapy at the time of TURBT

PI: Michael O'Donnell

[NCT05538663](#)

NEOADJUVAN

T

EA8192

Criteria: High grade upper tract urothelial carcinoma proven by biopsy with 12 weeks of randomization; no component of small cell/neuroendocrine carcinoma; no evidence of metastatic disease or enlarged LN

PI: Umar Farooq

[NCT04628767](#)

V940-005

Criteria: muscle-invasive urothelial carcinoma

PI: Mohammed Milhem

[NCT06305767](#)

ADJUVANT

V940-005

Criteria: muscle-invasive urothelial carcinoma; high-risk pathologic disease after radical resection


PI: Mohammed Milhem

[NCT06305767](#)

BLADDER CANCER

OPEN

PENDING




PROSTATE CANCER



OPEN




PENDING



KIDNEY CANCER

OPEN


PENDING



KIDNEY CANCER

☐ OPEN

☐ PENDING



Gynecologic Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

OVARIAN CANCER



OPEN



PENDING

LOW GRADE SEROUS CARCINOMA

NRG-GY019 :

Criteria: Newly diagnosed, stage II-IV low-grade serous ovarian, fallopian tube and primary peritoneal cancers; must have undergone an attempt at maximal upfront cytoreductive surgery, with either optimal (≤ 1 cm diameter residual disease/nodule) or suboptimal residual disease (> 1 cm diameter residual disease/nodule) allowed; must enroll within 8 weeks of primary surgery

PI: David Bender

[NCT04095364](#)

HIGH GRADE SEROUS CARCINOMA

GOG-3078-GLORIOSA (Maintenance therapy):

Criteria: Recurrent (1st recurrence), platinum-sensitive high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer; FRα-High; subjects who have not progressed after second-line platinum-based chemotherapy plus bevacizumab; prior PARP required if BRCA mutated; must be randomized within 8 weeks from last dose of platinum-based triplet therapy

PI: David Bender

[NCT054457](#)

[78](#)

GOG-3086 REFRAme-01:

Criteria: Recurrent, platinum-resistant high-grade serous ovarian, fallopian tube, or primary peritoneal cancer; FOLR1 expression $\geq 25\%$ on central lab screening IHC testing; measurable disease required; Up to 3 prior regimens – no prior FOLR1-targeting ADC; prior bevacizumab required unless contraindicated

PI: David Bender


[NCT058707](#)

[48](#)

OVARIAN CANCER

OPEN

PENDING



ENDOMETRIAL CANCER

☐ OPEN

☐ PENDING

NEWLY DIAGNOSED
HER2+

NRG-GY026 :
Criteria: stage IA-IVB, non-recurrent, chemo-naïve, HER2+ endometrial serous carcinoma or endometrial carcinosarcoma; must have myoinvasive disease; must be within 8 weeks of primary surgery (or endometrial biopsy in patients who never undergo hysterectomy) at the time of study registration; no prior radiation therapy, biologic, or targeted therapy for endometrial cancer
PI: David Bender

[NCT05256225](#)

RECURRENT
dMMR


NRG-GY025:
Criteria: Recurrent MMR-deficient endometrial cancer; serous and carcinosarcoma subtypes excluded; measurable or detectable disease required; patients may have received up to 2 prior lines of systemic therapy; prior anti-PD1/PDL1 therapy is allowed if given in combination with chemotherapy or radiation therapy in adjuvant or primary metastatic/recurrent settings; must have had a complete response and have disease progression/relapse with treatment-free interval of 12 months or more from last dose of therapy with immune check inhibition
PI: David Bender

[NCT05112601](#)

ENDOMETRIAL CANCER

OPEN

PENDING



CERVICAL CANCER

☐ OPEN

☐ PENDING

METASTATIC

BGB-A317-A3055-101: A Phase 1 a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-A3055, Alone and in Combination With Tislelizumab in Patients With Selected Advanced or Metastatic Solid Tumors

PI: Muhammad Furqan

[NCT059350](#)

98

GERM CELL TUMOR



OPEN



PENDING

LOW OR STANDARD RISK

AGCT1531 :

Criteria: Low risk stage I immature teratoma (IT); site: ovarian; tumor markers: alpha-FP =< 1,000 ng/mL, beta-HCG institutional normal; all ages
Standard risk 2 (SR2)
Site: ovarian; stage: COG stage II and III, FIGO stage IC, II and III; histology: must contain at least one of the following: yolk sac tumor, embryonal carcinoma, or choriocarcinoma; age < 25

PI: David Dickens

[NCT03067](#)

[181](#)

INTERMEDIATE OR POOR RISK

AGCT1532:

Criteria: Histologically or cytologically confirmed germ cell; or Exceptionally raised tumour markers (AFP ≥ 1000ng/mL and/or HCG ≥ 5000 IU/L) without histologic or cytologic confirmation in the rare case where pattern of metastases consistent with GCT, high tumour burden, and a need to start therapy urgently; Primary arising in testis, ovary, retro-peritoneum, or mediastinum; Intermediate or poor prognosis as defined by IGCCC classification³

PI: David Dickens

[NCT025826](#)

[97](#)

BRCA1 OVARIAN CANCER RISK REDUCTION

OPEN

PENDING

INTERMEDIATE OR
POOR RISK


NRG-CC008:
Criteria: Individuals 35-50 years of age, inclusive; positive CLIA-approved test results for pathogenic or likely pathogenic germline BRCA1 mutation in the patient; non-randomized prospective trial comparing the non-inferiority of salpingectomy to salpingo-oophorectomy to reduce the risk of ovarian cancer among BRCA1 carriers; patient choice of bilateral salpingectomy or bilateral salpingo-oophorectomy (with or without hysterectomy); no prior radiation to the abdomen/pelvis; no prior hormonal therapy within 90 days *PI: David Bender*

[NCT042510](#)
[52](#)

Head and Neck Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155

HEAD AND NECK CANCER



☐ OPEN

☐ PENDING

HEAD AND NECK CANCER



OPEN



PENDING

HNSCC

**1L UNRESECTABLE OR
METASTATIC**

STELLAR-305:

Histologically or cytologically-confirmed R/M HNSCC that is considered incurable by local therapy; no prior systemic therapy administered in the recurrent or metastatic setting; therapy completed more than 6 months prior to randomization if given as part of multimodal treatment for locally advanced disease is allowed.

PI: Doug Laux

[NCT06082](#)

167

COMBINE-EGFR-1: A
Phase 1/2 Study of
REGN7075
(EGFRxCD28
Costimulatory
Bispecific Antibody) in
Combination With
Cemiplimab in Patients
With Advanced Solid
Tumors

PI: Doug Laux

[NCT046266](#)

35

GSK-219885 GALAXIES

Criteria:
The eligible primary tumor locations are oropharynx, oral cavity, hypopharynx, and larynx; Subjects must not have had prior systemic therapy administered in the R/M setting


PI: Doug Laux

[NCT06062420](#)

HEAD AND NECK CANCER

OPEN

PENDING



HEAD AND NECK CANCER

☐ OPEN

☐ PENDING

NASOPHARYN

GBAL

**Study to Evaluate
BL-B01D1:** Has
measurable
disease; LVEF
≥50%; must have
received platinum
and PD1

PI: Muhammad Furqan

[NCT059834](#)

32

HEAD AND NECK CANCER



OPEN



PENDING

THYROID

CANCER

EA3231:

Dedifferentiated thyroid cancer; BRAF V600E+; must have been previously treated with or deemed ineligible for treatment with Iodine-131; must have had prior treatment lenvatinib and/or sorafenib

PI: Doug Laux

[NCT06475989](#)

NON-MELANOMA SKIN CANCER

CUTANEOUS
SQUAMOUS CELL

1L

COMBINE-EGFR-1: A
 Phase 1/2 Study of
 REGN7075
 (EGFRxCD28
 Costimulatory
 Bispecific Antibody) in
 Combination With
 Cemiplimab in Patients
 With Advanced Solid
 Tumors

PI: Doug Laux

[NCT046266](#)

35

MERKEL, BASAL,
SCC

Replimune IGNYTE
 Criteria: Locally
 advanced or
 metastatic NMSC not
 considered treatable
 by surgery; must have
 received 8 wks of anti-
 PD1/PDL1 as their
 last line of therapy
 and progressed while
 on treatment

PI: Doug Laux

[NCT: 03767348](#)

MERKEL CELL

HCRN MCC20-443
 Criteria: Histological or
 cytological evidence of
 Merkel cell cancer per
 AJCC, 8th ed; presence
 of somatostatin
 receptors by Ga-68
 dotatate imaging;
 progress on treatment
 with anti-PD1/L1
 administered either as
 monotherapy or in
 combination with other
 check point inhibitors
 or other therapies

PI: Doug Laux

[NCT: 05583708](#)

☐ OPEN
 ☒ PENDING

Leukemia

Clinical Trials

Clinical Trials Hotline: 319-353-8155

ACUTE MYELOID LEUKEMIA (AML)



OPEN



PENDING

NEWLY
DIAGNOSED

MM1YA-S01:
Newly diagnosed
untreated AML, high-risk
AML; therapy-related
AML, AML with
myelodysplasia related
changes are eligible; FLT3
and t(9;22) excluded

PI: Prajwal Dhakal

[NCT05554406](#)

MM1YA-CTG01:
Must have been
assigned to this
study based on
presence of an
actionable mutation
following screening
on MYELOMATCH;
Age 18-59 at time of
induction

PI: Prajwal Dhakal

[NCT05554393](#)

KO-MEN-007
Criteria: Newly
diagnosed or
relapsed/refractory
AML with NPM1 or
KMT2A
rearrangement

PI: Grerk Sutamtewagul

[NCT: 05735184](#)

OncoVerity
A Study Comparing
Venetoclax and
Azacitidine Plus
Cusatuzumab to
Venetoclax and
Azacitidine in Newly
Diagnosed AML
Ineligible for Intensive
Therapy

PI: Grerk Sutamtewagul

[NCT06384261](#)

MYELOMATCH:
A Screening Study to
Assign People With
Myeloid Cancer to a
Treatment Study or
Standard of Care
Treatment Within
myeloMATCH

PI: Prajwal Dhakal

[NCT05564390](#)

MM10A-EA02:
Must have been
assigned to this
study based
screening from
MYELOMATCH;
must be ≥60 years of
age or <60 and
better served by
azanucleoside-based
therapy rather than
intensive therapy
based on clinical
status

PI: Prajwal Dhakal

[NCT06317649](#)


ACUTE MYELOID LEUKEMIA (AML)



OPEN



PENDING



MALIGNANT HEME (OTHER)

☐ OPEN

☐ PENDING

NEWLY DIAGNOSED
MDS

SY-1425-301

Criteria: Must be RARA-positive based on investigational assay; diagnosis of MDS according to WHO classification and classified as very high, high, or intermediate risk per IPSS

PI: Greer Sutamtewagul

[NCT: 04797780](#)

MF, MDS,
MDS/MPN, ET

LIMBER

Criteria: Received at least 1 prior line of therapy; R/R or intolerant to the last therapy; no therapy that would provide clinical benefit in the opinion of the investigator

PI: Kittika Poonsombudlert

[NCT04279847](#)

ANY MYELOID
MALIGNANCY

CA055-001

Criteria: Moderate or severe hepatic impairment as defined by National Cancer Institute Organ Dysfunction Working Group criteria

PI: Greer Sutamtewagul

[NCT: 05209295](#)

Lymphoma

Clinical Trials

Clinical Trials Hotline: 319-353-8155

LARGE CELL LYMPHOMAS



OPEN



PENDING

FRONTLINE

ZUMA-23
Study to Compare
Axicabtagene
Ciloleucel With
Standard of Care
Therapy as First-line
Treatment in
Participants With
High-risk Large B-cell
Lymphoma (ZUMA-23)

PI: Umar Farooq

[NCT05605899](#)

SKYGLO
An Open-Label Study
Comparing Glofitamab
and Polatuzumab
Vedotin + Rituximab,
Cyclophosphamide,
Doxorubicin, and
Prednisone Versus
Pola-R-CHP in
Previously Untreated
Patients With Large B-
Cell Lymphoma

PI: Eric Mou

[NCT06047080](#)

ANHL1931
Nivolumab in
Combination With
Chemo-Immunotherapy
for the Treatment of
Newly Diagnosed
Primary Mediastinal B-
Cell Lymphoma

PI: David Dickens

[NCT04759586](#)

Cholecalciferol in
Improving Survival in
Patients With Newly
Diagnosed Cancer With
Vitamin D Insufficiency

PI: Brian Link

[NCT01787409](#)

LARGE CELL LYMPHOMAS



OPEN



PENDING

RELAPSED/REFRACTORY

SGN35T-001:

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou

[NCT06120504](#)

JNJ-90014496

A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

PI: Umar Farooq

[NCT05421663](#)

JCAR017

A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL)

PI: Umar Farooq

[NCT04245839](#)

S2114

A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Grade IIIB Follicular Lymphoma

PI: Eric Mou

[NCT05633615](#)

LYL314-101

Study of IMPT-314 (CD19/CD20 bispecific CAR-T) in R/R Aggressive B-cell NHL

PI: Umar Farooq

[NCT: 05826535](#)

JNJ-90009530

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

PI: Umar Farooq

[NCT05784441](#)


LARGE CELL LYMPHOMAS



OPEN



PENDING



MANTLE CELL LYMPHOMA



OPEN



PENDING

FRONTLINE

A052101:

A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients (Age \geq 70 or \geq 60 with selected comorbidities) with Mantle Cell Lymphoma

PI: Umar Farooq

[NCT: 05976763](https://clinicaltrials.gov/ct2/show/study/NCT05976763)

RELAPSED/REFRACTORY

SGN35T-001:

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou

[NCT06120504](https://clinicaltrials.gov/ct2/show/study/NCT06120504)

ELM-2

A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With B-cell Non-Hodgkin Lymphoma That Have Been Previously Treated

PI: Umar Farooq

[NCT: 03888105](https://clinicaltrials.gov/ct2/show/study/NCT03888105)

BGB-16673

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

PI: Eric Mou

[NCT: 05006716](https://clinicaltrials.gov/ct2/show/study/NCT05006716)

FOLLICULAR LYMPHOMA

☐ OPEN

☐ PENDING

FRONTLINE

S2308: RANDOMIZED
PHASE III STUDY OF
MOSUNETUZUMAB
VS. RITUXIMAB FOR
LOW TUMOR
BURDEN FOLLICULAR
LYMPHOMA

PI: Eric Mou

[NCT06337318](#)


FOLLICULAR LYMPHOMA



OPEN



PENDING



CLL/SLL



OPEN



PENDING

FRONTLINE

BELLWAVE-011:

A Phase 3,
Randomized Study to
Compare
Nemtabrutinib
Versus Comparator
(Investigator's
Choice of Ibrutinib or
Acalabrutinib) in
Participants With
Untreated Chronic
Lymphocytic
Leukemia/Small
Lymphocytic
Lymphoma

PI: Eric Mou

[NCT06136559](#)

RELAPSED/REFRACTORY

BGB-16673

A Dose-Escalation and
Expansion Study of
BGB-16673 in
Participants With B-
Cell Malignancies

PI: Eric Mou

[NCT: 05006716](#)

HODGKIN LYMPHOMA

☐ OPEN

☐ PENDING

FRONTLINE

AHOD2131:
A Randomized Phase 3
Interim Response
Adapted Trial Comparing
Standard Therapy with
Immuno-oncology
Therapy for Children and
Adults with Newly
Diagnosed Stage I and II
Classic Hodgkin
Lymphoma

PI: David Dickens

[NCT05675410](#)

RELAPSED/REFRACTORY

BTCRC HEM 15-027:
Phase I/II Study of
Nivolumab in
Combination with
Ruxolitinib in Relapsed
or Refractory Classical
Hodgkin Lymphoma

PI: Umar Farooq

[NCT03681561](#)

SGN35T-001:
An open-label phase 1
study to evaluate the
safety of
SGN-35T in adults
with advanced
malignancies

PI: Eric Mou

[NCT06120504](#)

T-CELL LYMPHOMA



OPEN



PENDING

FRONTLINE

A051902:

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative (<10%) Peripheral T-Cell Lymphomas

PI: Umar Farooq

[NCT: 04803201](#)

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

PI: Brian Link

[NCT01787409](#)

RELAPSED/REFRACTORY

SGN35T-001:

An open-label phase 1 study to evaluate the safety of SGN-35T in adults with advanced malignancies

PI: Eric Mou

[NCT06120504](#)

MB-105:

A single arm, two-stage, Phase 2, open-label, multicenter study of MB-105 in patients with CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).


PI: Eric Mou

[NCT06120504](#)

OTHER LYMPHOMAS

OPEN

PENDING



Melanoma


Clinical Trials

Clinical Trials Hotline: 319-353-8155


CUTANEOUS MELANOMA

OPEN

PENDING



UVEAL MELANOMA



Myeloma


Clinical Trials

Clinical Trials Hotline: 319-353-8155

MULTIPLE MYELOMA

OPEN

PENDING



MULTIPLE MYELOMA

(CONT'D)



OPEN



PENDING

RELAPSED/REFRACTORY

Ascorbic Acid + Melphalan
High Dose Ascorbic Acid is hypothesized to have synergy with melphalan. This is a phase 1 dose escalation trial.

3+ prior lines of therapy
Prior exposure to IMiD, PI, Anti-CD38 antibody required

PI: Christopher Strouse

[NCT: 03602235](#)

C1071020 – Elranatamab + Carfilzomib / anti-CD47 antibody
Testing combinations with anti-BCMA bispecific antibody.

Arm 1: Elra + Carf
1-3 prior lines
Prior carfilzomib is OK

Arm 2: Elra + anti-CD47
3+ prior lines of therapy
Refractory to IMiD, PI, anti-CD38 antibody
PI: Hira Shaikh

[NCT: 05675449](#)

P-BCMA-ALLO1
Allogeneic anti-BCMA CAR-T cells.

EITHER
- 2+ prior lines of therapy
- Refractory to PI, IMiD, anti-CD38 antibody
OR
- 3+ prior lines of therapy
- Exposure to PI, IMiD, anti-CD38 antibody

PI: Christopher Strouse

[NCT: 04960579](#)

QUINTESENTIAL
Autologous anti-GPRC5d CAR-T cells

3+ prior lines
Prior treatment with anti-BCMA therapy is **required**

PI: Christopher Strouse

[NCT: 06121843](#)

LimiTEC

Limited duration therapy of teclistamab

Patients achieving VGPR or better after 6 cycles of teclistamab (less than 9).

Telephone consenting and remote monitoring is possible (no need to visit Iowa City)
PI: Hira Shaikh

[NCT05932680](#)

MonumentAL-8
Combination anti-GPRC5d bispecific antibody + anti-BCMA CAR T cells for high risk myeloma

3+ prior lines
Exposure to IMiD, PI, anti-CD38 antibody
“High Risk” myeloma = 1 of:
- Cyto t[4;14, t[14;16], or - 17p
- Baseline ISS Stage III
- Extramedullary plasmacytoma
No prior anti-BCMA therapy
PI: Christopher Strouse

[NCT06550895](#)

MULTIPLE MYELOMA

☐ OPEN

☐ PENDING

SMOLDERING MYELOMA

Ecog-Acrin 173
Phase 3 Pre-emptive tx
for high risk smoldering
myeloma
Dara-Rd x2 years
Vs
Rd x 2 years

"High Risk" SMM = 2 of these:

- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved

Dx in last 1 year, no myeloma defining criteria
Pl: Christopher Strouse

[NCT: 03937635](#)

Neuroendocrine Clinical Trials

Clinical Trials Hotline: 319-353-8155


NEUROENDOCRINE CANCER



OPEN



PENDING



Sarcoma

Clinical Trials

Clinical Trials Hotline: 319-353-8155


SARCOMA



OPEN



PENDING



SARCOMA



OPEN



PENDING

ANGIOSARCOMA

IGNYTE

Criteria: locally advanced or metastatic disease; at least 1 measurable and injectable lesion; must have received 8 weeks of anti-PD1 as last line of therapy and progressed while on treatment

PI: Doug Laux

[NCT: 03767348](#)

CHONDROSARCO

MIA

CHONQUER

Criteria: LA/metastatic chondrosarcoma grades 1, 2, 3, not eligible for a curative resection; have received 0-1 prior systemic treatments in LA/metastatic setting

PI: John Rieth

[NCT06127407](#)

INBRX-109

Criteria: Conventional chondrosarcoma, unresectable or metastatic (clear-cell, mesenchymal, extraskeletal myxoid, myxoid, and dedifferentiated chondrosarcoma are not eligible)

PI: Mohammed Milhem

[NCT: 04950075](#)

Thoracic Cancer Clinical Trials

Clinical Trials Hotline: 319-353-8155


NON-SMALL CELL LUNG CANCER



OPEN



PENDING



NON-SMALL CELL LUNG CANCER



OPEN



PENDING

METASTATIC 3RD

LINE 1

IMC-F106C-101: Criteria: Relapsed from, refractory to, or intolerant of standard therapies; or, in combination with standard therapies

PI: Muhammad Furqan

NCT04262466

OBT076-001: Criteria: Subject has received a maximum of two prior lines of cytotoxic chemotherapy in the metastatic setting; subject has tumor that is positive for CD205 antigen by IHC staining

PI: Doug Laux

[NCT040643](#)

59

SGNEGFRd2-001: A Phase 1 Study of SGN-EGFRd2 in Advanced Solid Tumors

PI: Muhammad Furqan

[NCT059831](#)

33

INBRX-106: Criteria: Locally advanced or metastatic, non-resectable disease, which has progressed despite all standard therapies including CPI or for whom no standard or clinically acceptable therapy exists

PI: Muhammad Furqan

[NCT0419](#)

8766

SGNPDL1v-001: SGN-PDL1V alone and with pembrolizumab in participants with solid tumors

PI: Doug Laux

[NCT0520](#)

8762

Study to Evaluate BL-B01D1:

Criteria: Has measurable disease; LVEF ≥50%

PI: Muhammad Furqan

[NCT059834](#)

32

KO-2806
Criteria: KRAS G12C; prior use of KRAS permitted

PI: Doug Laux

[NCT06026410](#)

SMALL CELL LUNG CANCER



OPEN



PENDING

1L

MOZART:
Criteria: Extensive disease IV SCLC, or T3-4 disease due to multiple lung nodules that are too extensive for radiation; No prior systemic therapy for small-cell lung cancer, with the following exceptions: Up to one cycle of platinum doublet chemotherapy with or without durvalumab is allowed up to 4 weeks prior to registration on this study
PI: Muhammad Furqan

[NCT05903092](https://clinicaltrials.gov/ct2/show/study/NCT05903092)

2ND LINE+

M23-385: Criteria: Histologically or cytologically confirmed SCLC that is relapsed or refractory (R/R) following at least 1 prior platinum-containing chemotherapy and with no curative therapy available

PI: Muhammad Furqan

[NCT05599984](https://clinicaltrials.gov/ct2/show/study/NCT05599984)

Study to Evaluate BL-B01D1: Has measurable disease; LVEF ≥50%

PI: Muhammad Furqan

[NCT05983432](https://clinicaltrials.gov/ct2/show/study/NCT05983432)

BTCRC-LUN20-462
Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

PI: Muhammad Furqan

[NCT: 04919382](https://clinicaltrials.gov/ct2/show/study/NCT04919382)

Cancer Services – Quad Cities Clinical Trials

Clinical Trials Hotline: 319-353-8155

THORACIC CANCER



OPEN



PENDING

SCLC

BTCRC-LUN20-462

Criteria: Histologically or cytologically documented diagnosis of extensive stage SCLC and have progressed or recurred after platinum-based chemotherapy with immunotherapy; max of 2 prior lines of systemic therapy in the metastatic setting

PI: Muhammad Furqan

[NCT: 04919382](#)

BREAST CANCER

TRIPLE
NEGATIVE

SCARLET: T2-T4, N0, M0 or T1-T3, N1-2, M0; no prior systemic therapy or radiation therapy with curative intent for current breast cancer

PI: Sneha Phadke

[NCT05929768](#)

Optim-ICE: T1cN1-2 or T2-4N0-2; no residual disease or LN after neoadjuvant therapy; neoadjuvant chemo+pembro x 6 cycles; < 12 weeks between surgery and randomization

PI: Sneha Phadke

[NCT05812807](#)

☐ OPEN

☐ PENDING

ER+

Cambria: must have had definitive locoregional therapy +/- adjuvant systemic therapy; completed at least 2 yrs (but no more than 5) of adjuvant ET (and is still receiving)

PI: Sneha Phadke

[NCT05774951](#)

ADE-MI: HR+HER2- who are prescribed abemaciclib

PI: Sneha Phadke

[NCT06169371](#)

BR009: premenopausal; postoperative pT1-3; ipsilateral nodes pN0 or pN1; if node negative, oncotype DX RS RS 21-25 or 16-20 with high clinical risk disease; if 1-3 nodes+ oncotype DX RS 26

PI: Sneha Phadke

[NCT05879926](#)

HEAD AND NECK CANCER



OPEN



PENDING

THYROID

CANCER

EA3231:

Dedifferentiated thyroid cancer; BRAF V600E+; must have been previously treated with or deemed ineligible for treatment with Iodine-131; must have had prior treatment lenvatinib and/or sorafenib

PI: Doug Laux

[NCT06475989](#)

GI CANCER

☐ OPEN

☐ PENDING

COLON

NRG-GI008
Criteria: T1-3, N1/N1c confirmed adenocarcinoma with RO resection; no radiographic evidence of overt metastatic disease; distal extent of tumor ≥ 12 cm from anal verge on colonoscopy or above peritoneal reflection as documented during surgery or on path specimen; must have had en bloc complete gross resection of tumor (curative resection); microsatellite stable or intact mismatch repair proteins through CLIA approved testing
PI: Saima Sharif

[NCT: 05174169](#)

GEJ

A022102
Criteria: Unresectable or metastatic HER2-adenocarcinoma of esophagus, GEJ, or stomach; no prior treatment for unresectable or metastatic disease

PI: Saima Sharif

[NCT05677490](#)

MULTIPLE MYELOMA

SMOLDERING MYELOMA

Ecog-Acrin 173

Phase 3 Pre-emptive tx
for high risk smoldering
myeloma

Dara-Rd x2 years

Vs

Rd x 2 years

"High Risk" SMM = 2 of these:

- >2.0 g/dl m-protein
- Cyto: +1q, t[4;14], -17p, -13q
- >20% PCs in marrow
- Involved light chains 20x greater than uninvolved

Dx in last 1 year, no myeloma
defining criteria

PI: Christopher Strouse

[NCT: 03937635](#)



OPEN



PENDING

NEWLY DIAGNOSED

S2209

Phase 3 evaluation
comparing up front 3 drug
regimens with single or
double agent maintenance

No prior treatment for MM

Myeloma Frailty Score=
frail or intermediate risk
regardless of age

PI: Hira Shaikh

[NCT05561387](#)